Actively Recruiting
Study of Clascoterone Cream 1% for Treating Moderate to Severe Facial Acne Vulgaris in Patients Aged 12 and Older
Led by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Updated on 2025-07-09
692
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Clascoterone Cream 1% compared to a placebo cream for treating moderate to severe facial acne vulgaris. This study is a phase 3, randomized, double-blind clinical trial aimed at determining how well Clascoterone Cream works in reducing acne lesions and improving the Investigators Global Assessment score over 12 weeks. Participants will be randomly assigned to receive either Clascoterone Cream 1% or a vehicle cream that looks and feels like the active treatment but contains no active ingredients. Both creams are applied twice daily for 12 weeks. The study groups include an experimental arm using Clascoterone Cream and a placebo comparator arm using the vehicle cream. During the 12-week study, participants will undergo regular evaluations of their acne, including counts of inflammatory and non-inflammatory lesions and overall lesion counts. The main outcomes measured are the percentage of participants achieving success in the Investigators Global Assessment and changes in lesion counts from baseline. Safety and adherence will be monitored throughout the trial, and participants will be followed until the study ends in October 2026.
CONDITIONS
Brief Title
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here